What is DNAtrix?
DNAtrix is a clinical-stage biotechnology firm specializing in the engineering of oncolytic viruses designed to selectively target and eradicate malignant cells. By leveraging a modified common cold virus, the company's platform offers a precision-medicine approach to oncology, minimizing collateral damage to healthy tissue. The firm's market position is anchored by its lead candidate, DNX-2401, which is currently positioned for global Phase 3 clinical evaluation in recurrent glioblastoma patients. Furthermore, the company is actively exploring the therapeutic potential of DNX-2440 for colorectal cancers with liver metastasis, positioning itself as a significant player in the competitive landscape of viral-based immunotherapy and pediatric rare disease treatment.
How much funding has DNAtrix raised?
DNAtrix has raised a total of $41.9M across 12 funding rounds:
Other Financing Round
$479K
Other Financing Round
$170K
Other Financing Round
$4.5M
Private Equity
$885K
Multiple Rounds
$2.5M
Grant
$10.8M
Series B
$20M
Grant
$2M
Debt
$350K
Other Financing Round (2008): $479K led by Mercury Fund
Other Financing Round (2010): $170K supported by Mercury Fund
Other Financing Round (2012): $4.5M featuring Mercury Fund
Private Equity (2012): $885K, investors not publicly disclosed
Other Financing Round (2013): $160K with participation from Mercury Fund
Other Financing Round (2013): $840K led by Mercury Fund
Series A (2013): $1.5M, investors not publicly disclosed
Grant (2014): $10.8M featuring Cancer Prevention & Research Institute of Texas
Series B (2014): $20M backed by Targeted Technology Fund, Mercury Fund, and Morningside Ventures
Grant (2016): $2M with participation from U.S. Food & Drug Administration
Debt (2020): $350K led by PPP
Key Investors in DNAtrix
Mercury Fund
A venture capital firm focused on early-stage investments in software and life science companies, providing the foundational capital necessary for long-term growth.
Targeted Technology Fund
A specialized investment firm that focuses on early-stage companies advancing disruptive technologies in medical devices, biotechnology, and life science tools to improve patient outcomes.
Cancer Prevention & Research Institute of Texas
A state-level agency dedicated to funding groundbreaking cancer research and prevention programs to accelerate the development of innovative therapies.
What's next for DNAtrix?
Looking ahead, the strategic focus for DNAtrix remains the successful execution of its global pivotal Phase 3 clinical study for DNX-2401. The company is well-positioned to leverage its recent capital influx to accelerate the development of its secondary pipeline, including the ongoing Phase 1 testing of DNX-2440. As the firm approaches critical regulatory milestones, including potential FDA submissions for its rare pediatric disease designations, the emphasis will likely shift toward commercialization readiness and potential strategic partnerships. The integration of robust clinical data with continued financial discipline will be essential as DNAtrix transitions from a research-heavy entity to a late-stage clinical developer with the potential to disrupt standard-of-care protocols in neuro-oncology and beyond.
See full DNAtrix company page
